Quality Systems — Final Revision Notes UPSC Drug Inspector Exam 2026
Subject: UPSC Drug Inspector Exam 2026
Subject: UPSC Drug Inspector Exam 2026
GMP: That part of Quality Assurance which ensures products are consistently produced and controlled to quality standards appropriate to their intended use and as required by the marketing authorization
Legal basis in India: Schedule M of Drugs & Cosmetics Rules, 1945 (mandatory condition of manufacturing license)
Schedule M — GMP for drugs (allopathic); Schedule M-I — Homeopathic; Schedule M-II — Cosmetics; Schedule M-III — Medical Devices; Schedule T — Ayurvedic/Siddha/Unani
Revised Schedule M notified 28 December 2023 (G.S.R. 922(E)) — aligned with WHO GMP & PIC/S concepts:
New concepts introduced: Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), Product Quality Review (PQR), Qualification & Validation of equipment, Computerized systems validation, Pharmacovigilance obligations for manufacturers, Change control, Deviation management, CAPA
Implementation timeline: manufacturers with turnover > ₹250 crore — 6 months; MSMEs (≤ ₹250 crore) — 12 months (subsequently extended by Govt — know the concept, check latest status)
WHO GMP: text available as WHO Technical Report Series (TRS No. 986, Annex 2 etc.); WHO Certification Scheme (COPP — Certificate of Pharmaceutical Product) for exports
Quality Assurance (QA): widest concept — the sum total of organized arrangements made to ensure products are of quality required for intended use; includes GMP + other factors (product design, development)
GMP: part of QA — ensures consistent production & control
Quality Control (QC): part of GMP — concerned with sampling, specifications, testing, documentation & release procedures; ensures materials/products not released until quality judged satisfactory
Hierarchy: QA ⊃ GMP ⊃ QC
Warehousing area — separate areas for quarantine, rejected, returned materials; sampling area
Production area — logical layout, dedicated/self-contained facilities for penicillins, cephalosporins, sex hormones, cytotoxics, certain biologicals (separate air handling)
Ancillary areas — rest rooms, canteen, changing rooms (airlocks)
Quality Control area — separate from production; instrument lab, chemical lab, microbiology lab (aseptic)
Personnel — head of production & head of QC independent of each other; both report to top management; neither can be responsible to the other; adequate trained staff; health checks
Health, clothing & sanitation — medical examination at recruitment & periodically; no direct hand contact with product; protective clothing
Manufacturing operations & controls — SOPs, master formula records, batch records, environmental monitoring
Sanitation in manufacture — premises free from insects/rodents
Raw materials — identity testing of each container/accepted sampling plan; quarantine before release; FIFO/FEFO (First Expiry First Out)
Equipment — designed, located, maintained to suit operation; cleaning logs; qualification: DQ → IQ → OQ → PQ
Documentation & records — Master Formula Record (MFR), Batch Manufacturing Record (BMR), batch packaging records, SOPs, logbooks; retention: batch records 1 year after expiry (or per revised rules — 5 years in some categories)
Labels & printed materials — controlled storage, issue, reconciliation
Quality audits — self-inspection/internal audit by designated team
Quality control system — specifications, testing, stability
Specification — raw material, in-process, finished product specs
Master formula — name, strength, complete list of ingredients, quantities, processing details
Reprocessing & recovery — only per validated procedures
Product containers/closures — comply with pharmacopoeial requirements
Validation — process validation, cleaning validation, analytical method validation; prospective, concurrent, retrospective, revalidation
Complaints & product recalls — written SOP; designated person; prompt recall; records
Returned goods — quarantine, evaluated before restocking
Site master file — document describing GMP-related activities at site
Sterile products (parenterals, ophthalmics) — clean rooms, grades of air cleanliness
APIs, biologicals, radiopharmaceuticals, metered-dose inhalers, etc.
| Grade | Equivalent (EU/WHO) | Max particles ≥0.5 µm/m³ (at rest) | Typical use |
|---|---|---|---|
| Grade A | ISO 5 | 3,520 | High-risk operations: filling zone, open ampoules/vials (laminar airflow) |
| Grade B | ISO 5 (at rest) | 3,520 | Background for Grade A (aseptic filling) |
| Grade C | ISO 7 (at rest) | 352,000 | Less critical stages of sterile manufacture |
| Grade D | ISO 8 (at rest) | 3,520,000 | Background/least critical clean areas |
Air changes: Grade B/C/D typically ≥20 air changes/hour; Grade A = unidirectional (laminar) flow 0.36–0.54 m/s (0.45 m/s ±20%)
Pressure differential between adjacent rooms: 10–15 Pascals
Environmental monitoring: settle plates, contact plates, active air sampling, personnel monitoring (glove prints)
Older classification (FS 209E): Class 100 = ISO 5; Class 10,000 = ISO 7; Class 100,000 = ISO 8 (still asked in exams!)
Batch/Lot: defined quantity of material processed in one process/series so it is homogeneous
Batch number: distinctive combination of numbers/letters to trace complete history
Quarantine: status of materials isolated physically or by other means pending decision on release/rejection
Validation: documented act of proving that any procedure/process/equipment consistently leads to expected results
Qualification: DQ (Design), IQ (Installation), OQ (Operational), PQ (Performance)
Calibration: comparing instrument readings against a standard of known accuracy
Change control: formal system to evaluate & approve changes to facilities, processes, documents
Deviation: departure from approved instruction/standard — must be documented & investigated
CAPA: Corrective Action (eliminate cause of detected nonconformity) & Preventive Action (eliminate cause of potential nonconformity)
OOS (Out of Specification): result failing specification — investigated per SOP
Reprocessing: reworking a batch using same materials by repeating one/more steps; Recovery: incorporating part of earlier batch into another
Self-inspection/internal audit: periodic review of GMP compliance by own trained team
Master documents: Site Master File, Validation Master Plan, Quality Manual
Cross-contamination prevention: dedicated facilities for sensitizing materials (penicillin, β-lactams, hormones, cytotoxics), airlocks, pressure cascades
Water systems: Purified Water (PW), Water for Injection (WFI) — WFI produced by distillation (or equivalent); storage at >70°C circulation; microbial limits: PW ≤100 CFU/mL; WFI ≤10 CFU/100 mL, endotoxin <0.25 EU/mL
FEFO (First Expiry First Out) preferred over FIFO
Stability studies: real-time & accelerated (long-term 25°C/60%RH or 30°C/65%RH; accelerated 40°C/75%RH — ICH conditions for Zone III/IV; India is Climatic Zone IV)
GMP certificate / WHO-GMP (COPP) issued by State Licensing Authority/CDSCO for export
Joint inspections (CDSCO + State) for certain categories
Non-compliance → license suspension/cancellation (Rule 85)
GLP: quality system concerned with the organizational process and conditions under which non-clinical health & environmental safety studies are planned, performed, monitored, recorded, archived and reported
Purpose: ensure quality, reliability & integrity of safety data (toxicology, pharmacology, environmental studies) submitted to regulators
International standard: OECD Principles of GLP (OECD, 1981; revised 1997); India is a full adherent to OECD GLP / MAD (Mutual Acceptance of Data) since 2011
India: National GLP Compliance Monitoring Authority (NGCMA) — under Department of Science & Technology (DST), New Delhi; established 2002; grants GLP certification to test facilities (validity 3 years)
GLP applies to non-clinical studies only — NOT to clinical trials (that's GCP), NOT to routine QC testing (that's GMP/cGMP)
Test facility organization & personnel
Test Facility Management: ensures compliance, approves SOPs, ensures QA programme exists
Study Director (SD): single point of study control; responsible for overall conduct & final report; one study, one SD
Principal Investigator (PI): for multi-site studies — acts on behalf of SD at each site
Quality Assurance Programme (QAU): independent of study conduct; audits facilities, studies, reports; maintains master schedule
Facilities: separation of test systems, archives, waste disposal; prevent mix-ups/contamination
Apparatus, materials & reagents: calibrated, maintained, labelled with expiry
Test systems: animals/plants/microbes — acclimatization, identification, housing per animal welfare norms (CPCSEA in India)
Test & reference items: characterization, stability, storage, handling; receipt records
Standard Operating Procedures (SOPs): written, approved, current, accessible
Performance of the study: approved study plan/protocol; deviations documented & acknowledged by SD
Reporting of results: final report signed by SD; QA statement included
Storage & retention of records: archives; retention typically ≥10 years (as per regulatory requirement)
| Aspect | GLP | GMP | GCP |
|---|---|---|---|
| Applies to | Non-clinical safety studies | Manufacture of products | Clinical trials in humans |
| Objective | Data integrity/reliability | Product quality | Subject protection + data credibility |
| Standard | OECD GLP; NGCMA (India) | Schedule M; WHO GMP | NDCT Rules 2019; ICH-GCP E6 |
| Key role | Study Director | Production & QC heads | Principal Investigator + Ethics Committee |
GCP: international ethical & scientific quality standard for designing, conducting, recording and reporting trials involving human subjects
Origin: Declaration of Helsinki (WMA, 1964; latest revision 2013 Fortaleza) — ethical principles for medical research
ICH-GCP E6(R2) — harmonized guideline (1996; R2 2016)
India: Schedule Y (2005, largely superseded) → New Drugs and Clinical Trials (NDCT) Rules, 2019 (effective 19 March 2019) under D&C Act; Indian GCP guidelines by CDSCO (2001); ICMR National Ethical Guidelines (2017)
Core principles: ethics, risk-benefit, informed consent, protocol compliance, qualified staff, confidentiality, data integrity
Sponsor: individual/company/institution taking responsibility for initiation, management & financing
Investigator / Principal Investigator (PI): qualified person (per NDCT: postgraduate medical qualification + experience) responsible for trial conduct at site
Ethics Committee (EC):
Must be registered with CDSCO/CLA (registration valid 3 years)
Composition (NDCT Rules): minimum 7 members — Chairperson (from outside institution), Member Secretary, basic medical scientist (preferably pharmacologist), clinician, legal expert, social scientist/philosopher/theologian, lay person, plus (for biomedical research) pharmacologist/clinician; at least 50% members from outside the institution; at least one member unaffiliated
Reviews protocol, informed consent documents, compensation provisions; continuing review at least annually
Monitor (CRA): verifies trial conduct per protocol/GCP
Data Safety Monitoring Board (DSMB): independent — for serious risk trials
Central Licensing Authority (CLA = DCGI): grants permission for trials (Form CT-04? — applications CT-01/approval deemed after 90 days if no communication; for drugs discovered in India — 30 working days)
| Phase | Subjects | Purpose |
|---|---|---|
| Phase 0 (microdosing) | ~10 | Sub-therapeutic doses; PK/PD screening |
| Phase I | 20–100 healthy volunteers (patients for cytotoxics) | Safety, tolerability, MTD, PK/PD |
| Phase II | 100–300 patients | Therapeutic exploratory — efficacy, dose-ranging, short-term safety |
| Phase III | 300–3,000+ patients | Therapeutic confirmatory — efficacy vs standard/placebo, safety in large population |
| Phase IV | Post-marketing | Pharmacovigilance, rare ADRs, long-term effects, additional indications |
Academic clinical trials (investigator-initiated, non-regulatory purpose) — defined under NDCT Rules
BA/BE studies — bioavailability/bioequivalence: two-rate/two-period crossover design; Cmax, Tmax, AUC; 90% CI of ratio within 80–125% for bioequivalence
Compensation for trial-related injury/death (NDCT Rules): formula-based (age factor — like ₹8 lakhs base for death of... know: formula per age multiplier, e.g., W = monthly income factor); free medical management as long as required; Sponsor to report SAE within 24 hours to CLA/EC; EC forwards report on compensation; DCGI decides quantum; sponsor to pay within 30 days of order
SAE reporting: Investigator → Sponsor, EC, CLA within 24 hours of occurrence; detailed report within 14 days
Voluntary, written, signed & dated; in language the subject understands; Audio-Visual (AV) recording of consent mandatory for vulnerable subjects in trials of new chemical entities (per 2013 amendments — retained in NDCT framework)
Essential elements: purpose, procedures, risks, benefits, alternatives, confidentiality, compensation, contact, right to withdraw
Vulnerable populations: children (assent + parent/LAR consent), pregnant women, prisoners, illiterate (impartial witness)
IB: compilation of clinical & non-clinical data on investigational product
Protocol: document stating rationale, objectives, design, methodology, statistics, organization
CRF (Case Report Form): record of protocol-required data per subject
Source data/documents — original records; ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate; + Complete, Consistent, Enduring, Available)
TQM: organization-wide approach — customer focus, continuous improvement (Kaizen), employee involvement
PDCA cycle (Deming cycle): Plan → Do → Check → Act
ISO 9001 — Quality Management Systems (QMS); ISO 13485 — QMS for medical devices; ISO 17025 — competence of testing & calibration laboratories (NABL accreditation in India); ISO 14001 — environment; ISO 45001 — occupational health & safety
ICH Guidelines:
Q series (Quality): Q1 Stability, Q2 Analytical validation, Q3 Impurities, Q7 GMP for APIs, Q8 Pharmaceutical Development, Q9 Quality Risk Management, Q10 Pharmaceutical Quality System
S series (Safety), E series (Efficacy — E6 = GCP), M series (Multidisciplinary — M4 CTD)
CTD (Common Technical Document): 5 modules — M1 regional/admin, M2 summaries, M3 quality, M4 non-clinical, M5 clinical
Tools: FMEA (Failure Mode Effects Analysis), FTA, HACCP, risk ranking & filtering
Risk = severity × probability × detectability (RPN in FMEA)
| Guideline | Scope |
|---|---|
| GPP | Good Pharmacy Practice (FIP/WHO) — pharmacist services |
| GDP | Good Distribution Practice — storage, transport, cold chain |
| GSP | Good Storage Practice |
| GVP | Good Pharmacovigilance Practice |
| GEP | Good Engineering Practice |
| GRP | Good Regulatory Practice |
| GAMP | Good Automated Manufacturing Practice (computerized systems) |
| GLP | Non-clinical laboratory studies |
| GCP | Clinical trials |
| GMP | Manufacturing |
Process validation types: Prospective (before commercial distribution), Concurrent (during routine production), Retrospective (historical data), Revalidation (after change/periodic)
Cleaning validation: worst-case product selection, swab & rinse sampling, acceptance criteria (10 ppm criterion / 0.1% of therapeutic dose / visually clean)
Analytical method validation parameters (ICH Q2): accuracy, precision (repeatability, intermediate, reproducibility), specificity, linearity, range, LOD, LOQ, robustness, system suitability
Computerized system validation: 21 CFR Part 11 (US FDA) — electronic records/electronic signatures; audit trails
HVAC qualification; water system validation phases (Phase 1: 2–4 weeks; Phase 2: 2–4 weeks; Phase 3: 1 year)
"If it is not documented, it is not done"
SOP — Standard Operating Procedure; BMR/BPR — Batch Manufacturing/Packaging Record; MFR — Master Formula Record; logbooks (equipment, cleaning, calibration); CoA — Certificate of Analysis
Good Documentation Practices: indelible ink, no overwriting (single-line strike-through, initial & date), no backdating, attributable entries
AQL (Acceptable Quality Limit/Level): max % defective acceptable for sampling inspection
Sampling plans: √n+1 rule (traditional); ANSI/ASQ Z1.4 tables
Six Sigma: 3.4 defects per million opportunities; DMAIC (Define-Measure-Analyze-Improve-Control)
Kaizen (continuous improvement), 5S (Sort, Set in order, Shine, Standardize, Sustain), Poka-Yoke (error-proofing)
CDSCO — national regulator; NIB (National Institute of Biologicals), Noida — QC of biologicals; CDL Kolkata; IPC Ghaziabad — Pharmacopoeia & PvPI; NABL — lab accreditation; NGCMA (DST) — GLP certification; QCI — Quality Council of India
QA ⊃ GMP ⊃ QC — hierarchy question appears every year.
GMP legal basis = Schedule M; revised Dec 2023 — new: PQS, QRM, PQR, validation, pharmacovigilance; threshold ₹250 crore turnover.
Clean room grades A/B/C/D; Grade A = ISO 5 = old Class 100; pressure differential 10–15 Pa.
India = ICH Climatic Zone IV; accelerated stability 40°C/75% RH.
GLP = OECD principles; India — NGCMA under DST; Study Director = single point of control; India full OECD MAD adherent since 2011.
GCP roots = Declaration of Helsinki (1964); Indian law = NDCT Rules 2019; EC registration valid 3 years; EC minimum 7 members.
Trial phases: I = safety/healthy volunteers; II = efficacy/dose; III = confirmatory large-scale; IV = post-marketing.
BE acceptance: 90% CI within 80–125%.
SAE reporting by investigator within 24 hours.
Schedule M-I (Homeopathy), M-II (Cosmetics), M-III (Devices), T (Ayurveda).
ICH: Q9 = QRM, Q10 = PQS, E6 = GCP, M4 = CTD.
ISO 17025 = lab competence (NABL); ISO 13485 = devices QMS.
FEFO preferred; WFI by distillation, hot circulation >70°C.
Retention: batch records ≥ 1 year after expiry (typical); GLP archives ≥ 10 years.
Penicillins/cephalosporins/hormones/cytotoxics — dedicated facilities.
Most repeated MCQs: QA/GMP/QC hierarchy; Schedule M mapping; clean room grades; GLP Study Director; NDCT EC composition; phase-wise trial objectives.
Link with jurisprudence: GMP non-compliance → license suspension under Rule 85; manufacturing conditions under Rule 74/78.
Revised Schedule M (2023) is prime current-affairs material for 2026 — learn the five new concepts (PQS, QRM, PQR, validation, pharmacovigilance).
Distinguish validation vs qualification vs calibration vs verification — one-liner trap questions.
Don't confuse GLP (OECD/NGCMA) with GCP (NDCT/DCGI) with GMP (Schedule M/SLA) — regulator-matching questions are common.
Draw the trial-phase table and EC composition from memory.
For interviews: be ready to explain CAPA, deviation, change control, self-inspection with examples.
All the best for UPSC Drug Inspector 2026!